Triple Antigen vs Monoantigen Immunotherapy for Warts

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-20

Study Completion Date

2021-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Warts can be resistant to treatment or return despite the use of many therapeutic modalities. Combining immunotherapy might contribute to better response rates, particularly in recalcitrant warts, which is a real therapeutic challenge. The purpose of this study was to assess the effectiveness and safety of a triple intralesional immunotherapy combination composed of PPD, Candida antigen and MMR versus either agent alone in the management of multiple recalcitrant warts.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts

NCT05326152

Intralesional Versus Intramuscular Hepatitis B Vaccine for Multiple Common Warts

COMPLETED PHASE1/PHASE2

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

NCT05291845

Warts Human Papilloma Virus

RECRUITING PHASE2

Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts

NCT03183765

Common Wart Plantar Wart

COMPLETED PHASE4

Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts

NCT05761002

Human Papilloma Virus Anogenital Wart

UNKNOWN NA

Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts

NCT04288817

Common Wart

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study included 160 patients with multiple (\>3 warts) recalcitrant (at least 6 months duration and who did not respond to at least 2 treatment modalities) warts of different sites, size and duration, with or without distant warts after approval of the Institutional Review Board of Faculty of medicine, Zagazig university. They were randomly assigned to one of four groups (each with 40 patients): PPD, Candida antigen, MMR, or combination of the 3 antigens. Injections into the biggest wart were repeated every two weeks until clearance or for a total of five sessions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Triple Intralesional Immunotherapy Combination in Multiple Recalcitrant Warts

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel assignment

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Double masking

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

purified protein derivative (PPD)

Group A

Group Type ACTIVE_COMPARATOR